91 related articles for article (PubMed ID: 14498764)
1. Rapidly (and Successfully) Translating Novel Brain Radiotracers From Animal Research Into Clinical Use.
Shaw RC; Tamagnan GD; Tavares AAS
Front Neurosci; 2020; 14():871. PubMed ID: 33117115
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [
Lundmark F; Abouzayed A; Rinne SS; Timofeev V; Sipkina N; Naan M; Kirichenko A; Vasyutina M; Ryzhkova D; Tolmachev V; Rosenström U; Orlova A
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672390
[TBL] [Abstract][Full Text] [Related]
3. Strategies for the discovery and development of therapies for metastatic breast cancer.
Eckhardt BL; Francis PA; Parker BS; Anderson RL
Nat Rev Drug Discov; 2012 Jun; 11(6):479-97. PubMed ID: 22653217
[TBL] [Abstract][Full Text] [Related]
4. Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033.
Dorow DS; Cullinane C; Conus N; Roselt P; Binns D; McCarthy TJ; McArthur GA; Hicks RJ
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):441-52. PubMed ID: 16450138
[TBL] [Abstract][Full Text] [Related]
5. The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animals.
Roselt P; Meikle S; Kassiou M
Eur J Drug Metab Pharmacokinet; 2004; 29(1):1-6. PubMed ID: 15151164
[TBL] [Abstract][Full Text] [Related]
6. Positron-emission tomography for head and neck cancer.
Greven KM
Semin Radiat Oncol; 2004 Apr; 14(2):121-9. PubMed ID: 15095258
[TBL] [Abstract][Full Text] [Related]
7. Assessment of cancer-associated biomarkers by positron emission tomography: advances and challenges.
Collier TL; Lecomte R; McCarthy TJ; Meikle S; Ruth TJ; Scopinaro F; Signore A; VanBrocklin H; van De Wiele C; Waterhouse RN
Dis Markers; 2002; 18(5-6):211-47. PubMed ID: 14646039
[TBL] [Abstract][Full Text] [Related]
8. PET for in vivo pharmacokinetic and pharmacodynamic measurements.
Gupta N; Price PM; Aboagye EO
Eur J Cancer; 2002 Nov; 38(16):2094-107. PubMed ID: 12387835
[TBL] [Abstract][Full Text] [Related]
9. Fundamentals of positron emission tomography and applications in preclinical drug development.
Cherry SR
J Clin Pharmacol; 2001 May; 41(5):482-91. PubMed ID: 11361044
[TBL] [Abstract][Full Text] [Related]
10. Application of cardiac molecular imaging using positron emission tomography in evaluation of drug and therapeutics for cardiovascular disorders.
Yoshinaga K; Chow BJ; dekemp RA; Thorn S; Ruddy TD; Davies RA; DaSilva JN; Beanlands R
Curr Pharm Des; 2005; 11(7):903-32. PubMed ID: 15777243
[TBL] [Abstract][Full Text] [Related]
11. Applications of positron emission tomography in the development of molecular targeted cancer therapeutics.
Solomon B; McArthur G; Cullinane C; Zalcberg J; Hicks R
BioDrugs; 2003; 17(5):339-54. PubMed ID: 14498764
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
